Phoenix Bio

研究発表

研究発表

Modeling of hepatitis B virus infection spread in primary human hepatocytes

    Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
    J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

    Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

      Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
      Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

      miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

        Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
        Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.

        Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

          Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
          JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

          Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

            Tanaka, Yasuhito
            Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

            Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening

              Nishitsuji, H. Naito, Y. Murakami, Y. Sugiyama, M. Mizokami, M. Shoji, I. Murata, T. Shimotohno, K.
              Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.

              Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems

                Nosaka, T. Naito, T. Akazawa, Y. Takahashi, K. Matsuda, H. Ohtani, M. Nishizawa, T. Okamoto, H. Nakamoto, Y.
                PLoS One. 2025 Mar 6;20(3):e0314581. doi: 10.1371/journal.pone.0314581.

                Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

                  Ide, M. Tabata, N. Murai, K. Yonemura, Y. Wang, Y. Ishida, A. Shirasaki, T. Kaneko, S. Ito, S. Honda, M. Yanagawa, H.
                  FEBS Lett. 2025 Jan 25. doi: 10.1002/1873-3468.15101.

                  Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene

                    Zhang, M. Mouzannar, K. Zhang, Z. Teraoka, Y. Piotrowski, J. Ishida, Y. Tateno-Mukaidani, C. Saito, T.Abe-Chayama, H. Chayama, K.Liang, T. J.
                    PLoS Pathog. 2025 Jan 9;21(1):e1012803. doi: 10.1371/journal.ppat.1012803.

                    Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver

                      Bao, H. Murakami, S. Tsuge, M. Uchida, T. Uchikawa, S. Fujino, H. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Hayes, C. N. Oka, S.
                      Viruses. 2024 Nov 6;16(11):1743. doi: 10.3390/v16111743.

                      Modelling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytes

                        Louis Shekhtman, Yuji Ishida, Masataka Tsuge, Vladimir Reinharz, Mikaru Yamao, Masaki Takahashi, Chise Tateno, Susan L. Uprichard, Harel Dahari, Kazuaki Chayama
                        JHEP Reports https://doi.org/10.1016/j.jhepr.2024.101311.

                        Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?

                          El Ekiaby, M. Tanaka, J. van Drimmelen, H. Allain, J. P. Lelie, N.
                          J Viral Hepat. 2024 Aug 10. doi: 10.1111/jvh.13990.

                          Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice

                            Duehren, S. Uchida, T. Tsuge, M. Hiraga, N. Uprichard, S. L. Etzion, O. Glenn, J. Koh, C. Heller, T. Cotler, S. J. Oka, S. Chayama, K. Dahari, H.
                            Virus Res. 2024 Aug 26;349:199451. doi: 10.1016/j.virusres.2024.199451.

                            Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice

                              Okada, H. Sakamoto, T. Nio, K. Li, Y. Kuroki, K. Sugimoto, S. Shimakami, T. Doi, N. Honda, M. Seiki, M. Kaneko, S. Yamashita, T.
                              Mol Ther Methods Clin Dev. 2024 Jun 24;32(3):101289. doi: 10.1016/j.omtm.2024.101289.

                              Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein

                                Kornyeyev, D. Song, Z. Eng, S. Soulette, C. Ramirez, R. Tang, J. Yue, Q. Subramanian, R. Zaboli, S. Moon, C. Tam, J. Brodbeck, J. Aggarwal, A. Diehl, L. Fletcher, S. P. Hyrina, A. Holdorf, M. M. Burdette, D.
                                Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0042024. doi: 10.1128/aac.00420-24.

                                Antiviral effect of peptoids on hepatitis B virus infection in cell culture

                                  Murayama, A. Igarashi, H. Yamada, N. Aly, H. H. Molchanova, N. Lin, J. S. Nishitsuji, H. Shimotohno, K. Muramatsu, M. Barron, A. E. Kato, T.
                                  Antiviral Res. 2024 Mar;223:105821. doi: 10.1016/j.antiviral.2024.105821.

                                  An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity

                                    Tang, L. Remiszewski, S. Snedeker, A. Chiang, L. W. Shenk, T.
                                    Antiviral Res. 2024 Jun;226:105888. doi: 10.1016/j.antiviral.2024.105888.

                                    A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA

                                      Watanabe, T. Hayashi, S. Zhaoyu, Y. Inada, H. Nagaoka, K. Tateyama, M. Tanaka, Y.
                                      J Gastroenterol. 2024 Apr;59(4):315-328. doi: 10.1007/s00535-023-02070-y. Epub 2024 Feb 5.

                                      Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes

                                        Shimizu, R. Murai, K. Tanaka, K. Sato, Y. Takeda, N. Nakasyo, S. Shirasaki, T. Kawaguchi, K. Shimakami, T. Nio, K. Nakaya, Y. Kagiwada, H. Horimoto, K. Mizokami, M. Kaneko, S. Murata, K. Yamashita, T. Honda, M.
                                        Hepatol Commun. 2024 Jan 5;8(1):e0351. doi: 10.1097/HC9.0000000000000351. eCollection 2024 Jan 1.

                                        Hepatitis B virus evades the immune system by suppressing the NF-kappaB signaling pathway with DENND2A

                                          Ide, M. Tabata, N. Yonemura, Y. Murai, K. Wang, Y. Ishida, A. Honda, M. Kaneko, S. Ito, S. Yanagawa, H.
                                          Microbiol Spectr. 2024 Jan 19:e0378523. doi: 10.1128/spectrum.03785-23.